Full Press Release Details
Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
YORK, March 5, 2025 - Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"),
a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the
closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per
gross proceeds to the Company from this offering are approximately $15.3 million, before deducting the approximately $0.8 million
in placement agent's fees and other offering expenses payable by the Company. Canaccord Genuity acted as the sole placement agent
Company intends to use the net proceeds from this offering for working capital and other general corporate purposes.
securities described above were offered pursuant to a registration statement on Form S-3 (File No. 333-268560), which was declared effective
by the Securities and Exchange Commission on December 6, 2022. A final prospectus supplement relating to the offering has been filed
with the SEC and is available on the SEC's website at http://www.sec.gov. Electronic copies of the final prospectus
supplement and accompanying base prospectus included in the registration statement may be obtained by contacting Canaccord Genuity LLC,
Attention: Syndicate Department, One Post Office Square, Suite 3000, Boston, MA 02109, or by email at prospectus@cgf.com.
Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid
is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk
of developing esophageal precancer and cancer. Lucid's EsoGuard Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, represent
the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early
detection of esophageal precancer in at-risk patients.
more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit
and Lucid Diagnostics